Trial Profile
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms ASSESS
- 23 Jul 2018 Status changed from active, no longer recruiting to completed.
- 21 Apr 2015 New trial record
- 01 Jun 2014 Interim results published in the British Journal of Ophthalmology.